Tetanus Vaccination Schedule

Introduction to Tetanus Vaccination

The Centers for Disease Control and Prevention recommends a primary series in childhood followed by Tdap at age 11-12 years and booster doses of either Td or Tdap every 10 years throughout life to ensure continued protection against tetanus and diphtheria 1, 2

Childhood Vaccination Schedule

The primary series for tetanus vaccination consists of three doses administered at 4-8 week intervals, followed by a fourth (reinforcing) dose 6-12 months after the third dose, as recommended by the Advisory Committee on Immunization Practices 3, 4
The fourth dose may be administered as early as 12 months of age if at least 6 months have elapsed since the third dose, according to the Centers for Disease Control and Prevention 3, 5

Adolescent and Adult Vaccination

The American Academy of Pediatrics recommends that persons aged 11-18 years should receive a single dose of Tdap, preferably at age 11-12 years 1, 6
The Centers for Disease Control and Prevention recommends that after receiving Tdap, booster doses of either Td or Tdap should be administered every 10 years throughout life to maintain protection 1, 2
The Advisory Committee on Immunization Practices recommends that adults aged ≥19 years who have never received Tdap should get one dose of Tdap regardless of when they last received a tetanus-containing vaccine, followed by either Td or Tdap boosters every 10 years 2, 7

Special Populations

The American College of Obstetricians and Gynecologists recommends that pregnant women should receive one dose of Tdap during each pregnancy, regardless of prior vaccination history 2, 8
The Centers for Disease Control and Prevention recommends that Tdap should be administered between 27-36 weeks' gestation, preferably during the earlier part of this period, for pregnant women 2, 8

Wound Management

The Advisory Committee on Immunization Practices recommends that for tetanus-prone wounds, a tetanus toxoid-containing vaccine is indicated when >5 years have passed since the last tetanus toxoid-containing vaccine dose 2, 7
The Centers for Disease Control and Prevention recommends that for persons ≥11 years who have not previously received Tdap or whose Tdap history is unknown, Tdap is preferred over Td for wound management 2, 7

Catch-up Vaccination

The American Academy of Pediatrics recommends that unvaccinated persons aged 7-18 years should receive a series of three tetanus and diphtheria toxoid-containing vaccines, which includes at least 1 Tdap dose 2, 7
The Centers for Disease Control and Prevention recommends that the preferred schedule is 1 dose of Tdap, followed by 1 dose of either Td or Tdap ≥4 weeks afterward, and 1 dose of either Td or Tdap 6-12 months later for unvaccinated persons aged 7-18 years 2, 7

Important Considerations

The Advisory Committee on Immunization Practices recommends that the vaccination series does not need to be restarted for those with incomplete history, regardless of the time elapsed between doses 2, 7
The Centers for Disease Control and Prevention recommends that current guidelines still recommend the 10-year booster schedule to ensure continued protection 1, 2

Pitfalls to Avoid

The American Academy of Pediatrics recommends that do not administer DTaP to persons aged ≥7 years; use Tdap or Td instead 7, 8
The Centers for Disease Control and Prevention recommends that do not miss the opportunity to administer Tdap to adults who have never received it, regardless of when they last received Td 2, 7

Tetanus Vaccination Guidelines

Special Populations

Adults in India who missed their primary immunization should receive a three-dose series: one dose of Tdap, followed by Td at least 4 weeks later, and a third dose of Td 6-12 months after the second dose, as recommended by the Centers for Disease Control and Prevention (CDC) 9, 10, 11

Wound Management Protocol

For clean, minor wounds, no tetanus toxoid is needed if the last dose was within 10 years, but Tdap is preferred if not previously received, or Td if the last dose was more than 10 years ago, according to the CDC 12, 11
For contaminated or severe wounds, tetanus toxoid is needed if the last dose was more than 5 years ago, and Tdap is preferred if not previously received, or Td, as recommended by the CDC 12, 11
Tetanus Immune Globulin (TIG) 250 units IM is required if the patient has not completed the primary series, and when both TIG and tetanus toxoid are indicated, they should be administered in separate syringes at different anatomic sites, as recommended by the CDC 12, 9, 13

Important Clinical Considerations

The CDC recommends that persons with unknown or uncertain vaccination histories should be considered to have had no previous tetanus toxoid doses and require both tetanus toxoid and TIG for contaminated or severe wounds 12, 9, 13
Absolute contraindication for tetanus toxoid includes a history of neurologic or severe hypersensitivity/anaphylactic reaction to a previous dose, as stated by the CDC 14, 15
The CDC advises against using DTaP in persons ≥7 years of age and recommends using Tdap or Td instead, and against restarting the vaccination series if doses are delayed, simply continuing from where the patient left off, and against giving tetanus boosters more frequently than every 10 years for routine immunization to avoid Arthus reactions 12, 15

Tetanus Booster Frequency in Elderly Individuals

Standard Booster Schedule for Elderly

The Advisory Committee on Immunization Practices (ACIP) recommends decennial (every 10 years) booster doses of either Td or Tdap throughout adult life, including for elderly individuals aged ≥65 years 16, 17
Since 2019, ACIP guidelines allow flexibility in vaccine selection, permitting either Td or Tdap for routine 10-year boosters, whereas previously only Td was recommended for subsequent doses after the initial Tdap 16, 17

Evidence Supporting 10-Year Intervals

Complete primary tetanus vaccination provides long-lasting protection of ≥10 years for most recipients, which forms the scientific basis for the decennial booster recommendation 18
The 10-year interval applies to routine prophylactic immunization and ensures continued protection against both tetanus and diphtheria 18, 19

When 5-Year Intervals Apply

For contaminated or tetanus-prone wounds (not clean, minor wounds), a tetanus booster is appropriate if >5 years have elapsed since the last tetanus-containing vaccine 18

Special Considerations for the Elderly Population

Serosurveys indicate that 49%-66% of adults ≥60 years lack protective levels of circulating antitoxin against tetanus, making adherence to the 10-year booster schedule particularly important in this age group 18

Clinical Algorithm for Elderly Patients

Administer Td or Tdap booster every 10 years if the patient has completed primary vaccination series 16, 17
For wound management, contaminated/severe wounds require a booster if the last dose was >5 years ago 18

Tdap Vaccination Guidelines for Elderly Adults

Introduction to Tdap Vaccination

The Advisory Committee on Immunization Practices (ACIP) recommends that all adults aged 19 years and older who have not yet received a dose of Tdap should receive a single dose, regardless of age, including those ≥65 years 20, 21, 22
Tdap should be administered regardless of the interval since the last tetanus or diphtheria toxoid-containing vaccine 20, 21
After receipt of Tdap, persons should continue to receive Td for routine booster immunization every 10 years 20, 21

Evolution of Tdap Guidelines

In 2006, Tdap was not licensed for use among adults aged >65 years, and the safety and immunogenicity were not studied during U.S. pre-licensure trials 23
In 2012, ACIP updated recommendations to include adults aged ≥65 years after reviewing safety and immunogenicity data 20, 21, 22
Current guidelines affirm that providers should not miss an opportunity to vaccinate persons aged ≥65 years with Tdap 24

Product Selection and Administration

When feasible, Boostrix should be used for adults aged ≥65 years; however, either Tdap product (Boostrix or Adacel) administered to a person ≥65 years is immunogenic and would provide protection 20, 21, 24
A dose of either vaccine may be considered valid 20, 21
Providers may administer the Tdap vaccine they have available to avoid missing vaccination opportunities 20, 21

Safety and Immunogenicity Evidence

Clinical trials included 1,104 participants receiving Boostrix and 1,170 receiving Adacel aged ≥65 years 22
The frequency and severity of adverse events in persons aged ≥65 years were comparable to those among persons aged <65 years 22
No increase in local or generalized reactions was observed compared with Td recipients 22
Postmarketing data from VAERS suggest the safety profile of Tdap in adults aged ≥65 years was comparable to Td vaccine 22
For Boostrix, immune responses to pertussis antigens were noninferior to those following a 3-dose primary DTaP series, with geometric mean concentrations increasing 7.4-fold to 13.7-fold over baseline 21, 22
For Adacel, a 4.4-fold to 15.1-fold increase in anti-pertussis antibodies was observed 21, 22

Clinical Algorithm for Tdap Vaccination

If a patient has never received Tdap, administer Tdap now 20, 21, 22
If a patient has previously received Tdap, administer Td for routine 10-year booster 20
For wound management, Tdap is preferred over Td if the person has not previously received Tdap 20
Administer tetanus-containing vaccine if ≥5 years since last dose for contaminated or tetanus-prone wound 20

Tetanus Vaccination Frequency in Emergency Department Patients

Critical Pitfalls to Avoid in the ED

The Centers for Disease Control and Prevention recommends that tetanus boosters should not be given more frequently than every 10 years for routine immunization, as this can cause Arthus reactions, which are severe local hypersensitivity reactions characterized by pain, swelling, and induration developing 4-12 hours post-injection, in patients with a history of previous tetanus toxoid doses 25, 26, 27
The Centers for Disease Control and Prevention advises against administering tetanus toxoid to patients with a history of Arthus reaction following a previous dose more frequently than every 10 years, even for wound management, to minimize the risk of recurrent reactions 25, 26, 27

Tetanus Vaccination Guidelines

Timing and Administration

The Centers for Disease Control and Prevention recommends that individuals who have completed their primary tetanus vaccination series and have had a tetanus shot within 5 years do not need a tetanus shot after stepping on a nail, as they are already protected 28
For individuals with a last tetanus shot 5-10 years ago, contaminated wounds like stepping on a nail require a tetanus shot, with Tdap preferred if never received before, otherwise Td is used 28, 29
If the last tetanus shot was more than 10 years ago, all wound types require a tetanus shot, with Tdap preferred if never received before, otherwise Td is used 28, 29
Individuals with unknown or incomplete vaccination history require both tetanus vaccine and tetanus immune globulin (TIG) for contaminated wounds like nail punctures, with TIG given in a separate syringe at a different anatomic site from the vaccine 28, 29

Wound Management

The Centers for Disease Control and Prevention recommends that individuals with contaminated wounds like nail punctures should obtain tetanus vaccination within 24-48 hours as part of standard wound management to ensure timely protection, although there is no urgent rush in the immediate hours after injury 28

Special Considerations

Puncture wounds from nails are considered tetanus-prone wounds because they are contaminated with dirt, soil, and create anaerobic conditions deep in tissue where Clostridium tetani thrives, triggering the 5-year rule rather than the 10-year rule 28

Tetanus Vaccination for Adults with Lost Follow-Up

Direct Recommendation

The Centers for Disease Control and Prevention recommends that adults with uncertain or undocumented tetanus vaccination history should be treated as unvaccinated and receive a complete 3-dose primary series: one dose of Tdap immediately, followed by Td at least 4 weeks later, and a third dose of Td 6-12 months after the second dose 30

Clinical Algorithm for Lost Follow-Up Patients

If the patient claims prior vaccination but has no documentation, consider serologic testing for tetanus and diphtheria antitoxin levels, and if both levels are >0.1 IU/mL, previous vaccination is presumed and only a single dose of Tdap is needed, as recommended by the Centers for Disease Control and Prevention 30
The preferred 3-dose schedule is: Dose 1: Tdap (immediately), Dose 2: Td ≥4 weeks after Tdap, and Dose 3: Td 6-12 months after the second dose, as recommended by the Centers for Disease Control and Prevention 30
Tdap can substitute for any one of the three doses in the primary series, but the preferred approach is Tdap first, as recommended by the Centers for Disease Control and Prevention 30
Do not use DTaP in persons aged ≥7 years—use Tdap or Td instead, as recommended by the Centers for Disease Control and Prevention 30

Tdap Administration Guidelines

Special Situations Permitting Shorter Intervals

The CDC recommends administering Tdap at intervals <10 years since the last Td during periods of increased community pertussis activity or outbreaks, particularly for adults with comorbid medical conditions who are at higher risk for pertussis complications 31, 32, 33
For contaminated or tetanus-prone wounds, Tdap is preferred over Td for adults vaccinated >5 years earlier who require tetanus prophylaxis and have not previously received Tdap 31, 32, 33
Adults who completed the primary series and received tetanus vaccine <5 years earlier do not require additional vaccination for wound management 31, 32

Clinical Algorithm for Decision-Making

For patients who have never received Tdap, the CDC recommends administering Tdap now, regardless of interval since last Td (even if <10 years) 31, 32
For patients previously vaccinated with Tdap, consider Tdap if <10 years since last dose during pertussis outbreaks 31, 32, 33

Critical Contraindications

Adults with a history of Arthus reaction following a previous tetanus toxoid-containing vaccine should not receive any tetanus toxoid-containing vaccine until >10 years after the most recent dose, even for wound management 31, 32

Adult Tetanus‑Diphtheria (Td/Tdap) Vaccination Guidelines

Primary Vaccination Series

The CDC recommends that adults who have never completed the childhood series receive a 3‑dose primary series: first dose preferably Tdap, second dose (Td or Tdap) given ≥ 4 weeks after the first, and third dose administered 6–12 months after the second dose. 34

Routine Booster Schedule

The CDC advises that, after the primary series, Td or Tdap boosters should be given every 10 years to sustain protection against tetanus and diphtheria. 34

Absolute Contraindications

The American Academy of Pediatrics (AAP) states that a history of anaphylaxis to any vaccine component is an absolute contraindication to receiving Td/Tdap. 35
The AAP also lists encephalopathy occurring within 7 days of a prior pertussis‑containing vaccine as an absolute contraindication; in such cases, Td (without pertussis) should be used instead of Tdap. 35

Precautions (Risk–Benefit Considerations)

If a patient experienced Guillain‑Barré syndrome ≤ 6 weeks after a tetanus toxoid dose, continuation of vaccination is permissible, but Tdap is preferred over Td. 35
For individuals with a progressive neurologic disorder or uncontrolled epilepsy, the pertussis component should be withheld and Td (without pertussis) administered. 35

CDC Tetanus Vaccination Schedules and Recommendations

Pediatric Primary Series (≤ 7 years)

The American Academy of Pediatrics recommends initiating the DTaP series at a minimum age of 6 weeks, with a total of five doses to complete the primary series (dose 1 at 6 weeks; dose 2 4–8 weeks later; dose 3 4–8 weeks after dose 2; dose 4 6–12 months after dose 3, earliest at 12 months if ≥6 months have elapsed; dose 5 at 4–6 years)【36】【37】.
Each pediatric dose should be 0.5 mL administered intramuscularly; the anterolateral thigh is the preferred site for infants, and the deltoid muscle for older children【38】【39】.
DTaP must not be given to children ≥ 7 years; Tdap or Td should be used instead because the higher diphtheria toxoid content of DTaP can cause severe reactions in older children and adults【38】【39】.

Adolescent Vaccination (11–18 years)

Adolescents who have completed the childhood DTaP series should receive a single dose of Tdap at age 11–12 years【36】【37】.
If the 11–12 year dose is missed, adolescents aged 13–18 years may receive Tdap provided the childhood series is complete【36】【37】.
The minimum age for the two licensed Tdap products is 10 years for Boostrix® and 11 years for Adacel™【36】【37】.

Adult Primary and Booster Schedule (≥ 19 years)

Adults who have never received Tdap should be given one dose immediately, regardless of the interval since any prior Td, followed by Td or Tdap boosters every 10 years【38】【39】.
Routine boosters are recommended at a 10‑year interval after completion of the primary series【38】【39】.
Adult doses are 0.5 mL given intramuscularly, preferably in the deltoid muscle【38】【39】.

Healthcare‑Worker Recommendations

All healthcare personnel who have not previously received Tdap should receive a single dose as soon as feasible; a repeat dose may be given as early as 2 years after the last Td if needed【38】【39】.
Priority vaccination should be given to workers with direct contact with infants younger than 12 months【38】【39】.

Contraindications and Precautions (All Ages)

Absolute contraindication: a history of anaphylaxis to any vaccine component【38】【39】.
Absolute contraindication: encephalopathy within 7 days of a prior pertussis‑containing vaccine; in this situation Td (not Tdap) should be used【38】【39】.

Common Clinical Pitfalls (All Ages)

Do not administer tetanus boosters more frequently than every 10 years for routine immunization, as this increases the risk of Arthus‑type hypersensitivity reactions【38】【39】.
Do not give DTaP to persons ≥ 7 years; use Tdap or Td instead to avoid severe reactions【38】【39】.
Do not delay Tdap when indicated; it should be given regardless of the interval since the last Td dose【38】【39】.

Documentation Requirements

Permanent vaccination records must include vaccine type, manufacturer, anatomic site, route, administration date, and the facility where it was given【38】【39】.
Patients should be encouraged to keep personal vaccination records to minimize unnecessary repeat vaccinations【38】【39】.